SMARTVALUE
Timeline
31 events since 2010Board
Capital
Filings
Financial
Other
201020122014201620182020202220242026
2025
Merger: absorbed by Newpharma Group1 point ▸
- Accounting effect, 01-04-2025
- The deed holds 4 more points.
Annual accounts 2025 filed PDFfull format · 36 days before the deadline
Merger proposal: to be absorbed by Newpharma GroupNewpharma Group holds all the shares · SUKHINO holds all the shares13 points ▸
- Incorporation, 30-12-2009
- 250 shares
- Newpharma Group holds all the shares
- Capital, €86,745,274, 67,500 shares
- SUKHINO holds all the shares
- Power of attorney, Téo Lizin, mentioned twice in the deed
- Power of attorney, Tom Van Baeveghem, mentioned twice in the deed
- Power of attorney, Ann-Sophie De Muynck, mentioned twice in the deed
- Power of attorney, Pieter-Jan Bols, mentioned twice in the deed
- Power of attorney, Harold Lenfant, mentioned twice in the deed
- Power of attorney, Thomas Verbergt, mentioned twice in the deed
- Power of attorney, Maurits Arnauw, mentioned twice in the deed
- Power of attorney, Wim Dedecker, mentioned twice in the deed
- The deed holds 10 more points.
4 directors appointedCASTELEIN, Kris Roger; GOETHAERT, Stefan Annie Willy Maria; VANDAMME, Stefaan Walter Alphons and WILLEMYNS, Jo Paul Maria Agnès Maurits · Legal-form conversion: from private limited company to public limited company · Capital of €61,500, 250 shares8 points ▸
- Net-asset statement, 31-03-2024
- Legal-form conversion, from private limited company to public limited company
- Capital, €61,500, 250 shares
- Power of attorney, Willem Muyshondt
- Director appointment, CASTELEIN, Kris Roger
- Director appointment, GOETHAERT, Stefan Annie Willy Maria
- Director appointment, VANDAMME, Stefaan Walter Alphons
- Director appointment, WILLEMYNS, Jo Paul Maria Agnès Maurits
- The deed holds 7 more points.
2024
Annual accounts 2024 filed PDFunclassified schema · 42 days before the deadline
Powers of attorney: Willem MUYSHONDT and Hendrik MuyshondtGeneral meeting of 15:00, 20243 points ▸
- General meeting, 2024
- Power of attorney, Willem MUYSHONDT (notaires associés à halle)
- Power of attorney, Hendrik Muyshondt (notaires associés à halle)
- The deed holds 1 more point.
2023
Appointment: EY Réviseurs d'Entreprises (statutory auditor)Permanent representative: Jourquin Gilles2 points ▸
- Auditor appointment, EY Réviseurs d'Entreprises (statutory auditor)
- Permanent representative, Jourquin Gilles
- The deed holds 1 more point.
Annual accounts 2022 filed PDFunclassified schema · 26 days before the deadline
2022
Back to profit net €190,625 The net result is €190,625, after 3 loss-making years.
Annual accounts 2021 filed PDFunclassified schema · 25 days before the deadline
2021
1 director appointed, 1 resignationResignation: JGO SRL · Permanent representatives: Jérôme Gobbesso and Gilles Jourquin · Appointment: GJ Lifesciences Management SRL · General meeting of 14-07-20215 points ▸
- General meeting, 14-07-2021
- Director resignation, JGO SRL
- Permanent representative, Jérôme Gobbesso (director and permanent representative)
- Director appointment, GJ Lifesciences Management SRL
- Permanent representative, Gilles Jourquin
- The deed holds 1 more point.
Annual accounts 2020 filed PDFunclassified schema · 3 days before the deadline
Permanent representative: GOBBESSOAppointment: B.D.O Réviseurs d'entreprise (commissaire pour les comptes statutaires) · General meeting of 05-01-20213 points ▸
- General meeting, 05-01-2021
- Permanent representative, GOBBESSO
- Auditor appointment, B.D.O Réviseurs d'entreprise (commissaire pour les comptes statutaires)
New directorJGO appointed, JGO resigned · Permanent representative: Jrérôme GOBBESSO · Legal-form conversion: from coöperatieve vennootschap met beperkte aansprakelijkheid to private limited company · General meeting of 23-12-20209 points ▸
- General meeting, 23-12-2020
- Legal-form conversion, from coöperatieve vennootschap met beperkte aansprakelijkheid to private limited company
- 250 shares
- Power of attorney, Frédéric JENTGES
- Director resignation, JGO
- Board rule, 1
- Director appointment, JGO (director (not named in the articles))
- Permanent representative, Jrérôme GOBBESSO
- Registered office clause, rue du Charbonnage 10B2, 4020 Wandre (Liège)
- The deed holds 3 more points.
2020
Weakest financial year net -€596,760 The net result drops to -€596,760, the lowest from 2010 to 2025.
Annual accounts 2019 filed PDFfull format · 14 days late
2019
Annual accounts 2018 filed PDFfull format · 6 days before the deadline
2018
Annual accounts 2017 filed PDFfull format · 21 days before the deadline
2017
Highest result from 2010 to 2025 net €2.0m ▲34.1% The operating result of €1.9m and the net result of €2.0m are both a record.
Equity above €2m equity €3.7m ▲119% Equity rises from €1.7m to €3.7m.
Annual accounts 2016 filed PDFfull format · 6 days before the deadline
2016
Equity above €1m equity €1.7m ▲816% Equity rises from €182,626 to €1.7m.
Annual accounts 2015 filed PDFfull format · 31 days late
2015
Annual accounts 2014 filed PDFfull format · 19 days late
2014
Annual accounts 2013 filed PDFfull format · 41 days before the deadline
2013
Annual accounts 2012 filed PDFfull format · on the deadline day
2012
Equity above €150,000 equity €173,678 ▲44.4% With a profit in every financial year since 2010, equity grows to €173,678.
Annual accounts 2011 filed PDFfull format · 15 days before the deadline
2011
Equity above €100,000 equity €120,276 ▲40.5% With a profit in every financial year since 2010, equity grows to €120,276.
Annual accounts 2010 filed PDFfull format · 1 day late
2010
Incorporation PDF15 publications in the Belgian Official Gazette, the last on 20-11-2025
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
SMARTVALUE has filed 15 sets of annual accounts, the latest for financial year 2025.1 In 2025 the company was absorbed by merger into Newpharma Group.2